Retrospective real-world adherence in patients with type 2 diabetes initiating once-daily liraglutide 1.8 mg or twice-daily exenatide 10 μg.

Malmenäs M, Bouchard JR, Langer J

Clinical therapeutics1 May 2013Cited by 42 (Europe PMC)

PMID23642290DOI10.1016/j.clinthera.2013.03.021PepBankPUB-23642290

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanObservational studyOther
In adults with type 2 diabetes, adjusted adherence was lower with exenatide than liraglutide, whose adherence was approximately 11% higher.
In plain wordsIn adults with type 2 diabetes, exenatide was linked to lower adjusted adherence than liraglutide.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseAdjusted adherence
Study
n = 3,623
Comparator
Liraglutide 1.8 mg once daily
Outcome group
Treatment adherence and retention · Whole body
Studied dose
10 μg twice daily · 12 monthsAs given in this study (human).
Measurements
Adjusted adherence difference
≈ 11%
liraglutide versus exenatide
Source sentences
Summary
After adjusting for confounding factors, patients receiving once-daily liraglutide 1.8 mg were ∼11% more adherent than patients receiving twice-daily exenatide 10 μg (95% CI, 7-14; P < 0.0001).
2 context sentences(design, population, supporting numbers)
Summary · context
The goal of this retrospective database analysis was to determine the factors affecting adherence over a 12-month follow-up period in adults with type 2 diabetes mellitus (DM) initiating once-daily liraglutide (1.8 mg) or twice-daily exenatide (10 μg).
Summary · context
A patient-centric claims database was used, covering the period January 2009 to December 2011.
Report a problemFND-2364229002
02HumanObservational studyOther
In adults with type 2 diabetes, liraglutide was linked to approximately 11% higher adjusted adherence than exenatide.
In plain wordsIn adults with type 2 diabetes, liraglutide was linked to higher adjusted adherence than exenatide.
Peptide
Liraglutide
Outcome
IncreaseAdjusted adherence
Study
n = 3,623
Comparator
Exenatide 10 μg twice daily
Outcome group
Treatment adherence and retention · Whole body
Studied dose
1.8 mg once daily · 12 monthsAs given in this study (human).
Measurements
Adjusted adherence difference
≈ 11%
liraglutide versus exenatide
Source sentences
Summary
After adjusting for confounding factors, patients receiving once-daily liraglutide 1.8 mg were ∼11% more adherent than patients receiving twice-daily exenatide 10 μg (95% CI, 7-14; P < 0.0001).
2 context sentences(design, population, supporting numbers)
Summary · context
The goal of this retrospective database analysis was to determine the factors affecting adherence over a 12-month follow-up period in adults with type 2 diabetes mellitus (DM) initiating once-daily liraglutide (1.8 mg) or twice-daily exenatide (10 μg).
Summary · context
A patient-centric claims database was used, covering the period January 2009 to December 2011.
Report a problemFND-2364229003
03HumanObservational studyOther
In adults with type 2 diabetes, exenatide was linked to higher odds of poor adherence than liraglutide.
In plain wordsIn adults with type 2 diabetes, exenatide was linked to higher odds of poor adherence than liraglutide.
Peptide
Exenatide (exendin-4)
Outcome
IncreasePoor adherence odds
Study
n = 3,623
Comparator
Liraglutide 1.8 mg once daily
Outcome group
Treatment adherence and retention · Whole body
Studied dose
10 μg twice daily · 12 monthsAs given in this study (human).
Measurements
Poor adherence odds ratio
1.33 ratio
exenatide versus liraglutide
Source sentences
Summary
The odds ratio for "poor" adherence (MPR <80%) with twice-daily exenatide 10 μg therapy compared with liraglutide 1.8 mg once-daily was 1.33 (95% CI, 1.16-1.53; P < 0.0001).
2 context sentences(design, population, supporting numbers)
Summary · context
The goal of this retrospective database analysis was to determine the factors affecting adherence over a 12-month follow-up period in adults with type 2 diabetes mellitus (DM) initiating once-daily liraglutide (1.8 mg) or twice-daily exenatide (10 μg).
Summary · context
A patient-centric claims database was used, covering the period January 2009 to December 2011.
Report a problemFND-2364229004
04HumanObservational studyOther
In adults with type 2 diabetes, liraglutide was linked to lower odds of poor adherence than exenatide.
In plain wordsIn adults with type 2 diabetes, liraglutide was linked to lower odds of poor adherence than exenatide.
Peptide
Liraglutide
Outcome
DecreasePoor adherence odds
Study
n = 3,623
Comparator
Exenatide 10 μg twice daily
Outcome group
Treatment adherence and retention · Whole body
Studied dose
1.8 mg once daily · 12 monthsAs given in this study (human).
Measurements
Poor adherence odds ratio
1.33 ratio
exenatide versus liraglutide
Source sentences
Summary
The odds ratio for "poor" adherence (MPR <80%) with twice-daily exenatide 10 μg therapy compared with liraglutide 1.8 mg once-daily was 1.33 (95% CI, 1.16-1.53; P < 0.0001).
2 context sentences(design, population, supporting numbers)
Summary · context
The goal of this retrospective database analysis was to determine the factors affecting adherence over a 12-month follow-up period in adults with type 2 diabetes mellitus (DM) initiating once-daily liraglutide (1.8 mg) or twice-daily exenatide (10 μg).
Summary · context
A patient-centric claims database was used, covering the period January 2009 to December 2011.
Report a problemFND-2364229005

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 2
21 Oct 2026, 18:59 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.